LEIE ACQUPAR Stock

LACQ

US52539T1079

Biotechnology & Medical Research

OTC Markets Traded

Ensysce Biosciences, Inc., formerly Leisure Acquisition Corp., is a clinical-stage biotech company. The Company is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. The primary focus of the Company is its small molecule program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, trypsin activated abuse protection (TAAP) opioid product candidate, PF614. In addition, the Company is developing multi-pill abuse resistant (MPAR) technology for overdose protection. The Company has also developed a delivery platform for large biomolecules utilizing single walled carbon nanotubes (SWCNT) to produce immunology and gene therapy products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
LACQ Stock

01/07/21	Ensysce Biosciences Closes on Merger with Leisure Acquisition Corp.	MT
30/06/21	Ensysce Biosciences, Inc. completed the acquisition of Leisure Acquisition Corp. from HG Vora Capital Management, LLC and others in a reverse merger transaction.	CI
29/06/21	Leisure Acquisition Corp. Announces Board Appointments	CI
08/06/21	Leisure Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
02/06/21	Leisure Acquisition Corp.(OTCPK:LACQ) dropped from NASDAQ Composite Index	CI
15/03/21	Leisure Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
01/02/21	Leisure Acquisition : to Pursue Merger With Ensysce Biosciences	MT
01/02/21	Leisure Acquisition Corp. Enters into Merger Agreement for Business Combination with Ensysce Biosciences, Inc. and Announces Executive Changes	CI
01/02/21	Ensysce Biosciences, Inc. entered into a definitive agreement to acquire Leisure Acquisition Corp. from HG Vora Capital Management, LLC and others for approximately $220 million in a reverse merger transaction.	CI
10/11/20	Leisure Acquisition Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
08/08/20	Leisure Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
16/07/20	Gateway Casinos & Entertainment Limited cancelled the acquisition of Leisure Acquisition Corp. in a reverse merger transaction.	CI
08/05/20	Leisure Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI

01/04/22	Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results	GL
01/02/22	Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program	GL
20/01/22	Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting	GL
04/01/22	Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614	GL
16/11/21	Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LEIE ACQUPAR	-.--%	+3.50%	-	-	89.01M
WUXI APPTEC CO., LTD.	+2.24%	+8.40%	+58.47%	+69.00%	68.22B
ARGENX SE	+4.66%	+8.90%	+16.93%	+85.41%	59.82B
LONZA GROUP AG	-0.60%	+1.73%	+24.32%	+94.40%	56.07B
BEONE MEDICINES AG	+2.55%	+15.52%	+30.43%	+120.17%	47.67B
IQVIA HOLDINGS INC.	+2.58%	+7.89%	+32.49%	+45.30%	45.95B
REVOLUTION MEDICINES, INC.	+4.09%	+6.37%	+228.06%	+899.75%	43.29B
CELLTRION, INC.	-0.47%	+9.38%	+27.53%	+52.40%	35.66B
GENMAB A/S	+3.80%	-1.00%	+98.16%	+66.79%	34.73B
INSMED INCORPORATED	+1.48%	+6.21%	-38.80%	+395.73%	25.47B
Average	+2.03%	+7.48%	+53.07%	+203.21%	46B
Weighted average by Cap.	+2.32%	+7.83%	+54.17%	+182.63%

LEIE ACQUPAR Stock

Stocks

LACQ

US52539T1079

Biotechnology & Medical Research

Latest news: LEIE ACQUPAR

Press Releases: LEIE ACQUPAR

Other Biotechnology & Medical Research

Company Profile